Industry News
New leukemia immune cell therapy shows promise
Feb 20, 2014
New findings on cell therapy to treat leukemia bring more encouraging news of the promise that this experimental area of cancer treatment holds for patients for whom conventional approaches do not work. Read More
New leukemia immune cell therapy shows promise
Feb 20, 2014
New findings on cell therapy to treat leukemia bring more encouraging news of the promise that this experimental area of cancer treatment holds for patients for whom conventional approaches do not work. Read More
Data shows Prolaris test predicts metastases in prostate cancer from biopsies
Feb 20, 2014
Myriad Genetics, Inc. has announced it has published data in the Journal of Urology demonstrating that its Prolaris test accurately predicted, based on biopsy specimens, which men would develop biochemical recurrence (BCR) or metastatic disease following radical prostate surgery. Read More
A method for the diagnosis and prognosis of melanoma, the most aggressive skin cancer, is patented
Feb 20, 2014
UPV/EHU researchers have developed a method for the diagnosis and prognosis of cutaneous melanoma, the type of skin cancer with the highest mortality rate. This method will help not only in the more effective early detection of this cancer, but also in the development of more personalised treatments. Read More
Data shows Prolaris test predicts metastases in prostate cancer from biopsies
Feb 20, 2014
Myriad Genetics, Inc. has announced it has published data in the Journal of Urology demonstrating that its Prolaris test accurately predicted, based on biopsy specimens, which men would develop biochemical recurrence (BCR) or metastatic disease following radical prostate surgery. Read More
A method for the diagnosis and prognosis of melanoma, the most aggressive skin cancer, is patented
Feb 20, 2014
UPV/EHU researchers have developed a method for the diagnosis and prognosis of cutaneous melanoma, the type of skin cancer with the highest mortality rate. This method will help not only in the more effective early detection of this cancer, but also in the development of more personalised treatments. Read More
Matching the right drug with the right ovarian tumor
Feb 20, 2014
There are three common drugs for advanced ovarian cancer: paclitaxel, cyclophosphamide, and topotecan. Like a shell game, if you pick the right drug a patient is likely to respond. And, unfortunately, picking the wrong drug can lead to treatment failure. Read More
Study finds more women receiving breast reconstruction after mastectomy
Feb 20, 2014
A new study finds that the majority of women who undergo mastectomy for breast cancer go on to get breast reconstruction, a practice that has increased dramatically over time.Researchers found that 46 percent of patients received reconstruction in 1998 but that figure rose to 63 percent by 2007."Breast reconstruction has a big impact on quality of life for breast cancer survivors. Read More
Matching the right drug with the right ovarian tumor
Feb 20, 2014
There are three common drugs for advanced ovarian cancer: paclitaxel, cyclophosphamide, and topotecan. Like a shell game, if you pick the right drug a patient is likely to respond. And, unfortunately, picking the wrong drug can lead to treatment failure. Read More
Study finds more women receiving breast reconstruction after mastectomy
Feb 20, 2014
A new study finds that the majority of women who undergo mastectomy for breast cancer go on to get breast reconstruction, a practice that has increased dramatically over time.Researchers found that 46 percent of patients received reconstruction in 1998 but that figure rose to 63 percent by 2007."Breast reconstruction has a big impact on quality of life for breast cancer survivors. Read More
Previous Page Next Page